Self‐control study on reduced‐dose depot versus daily administration of gonadotrophin‐releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles
Authors:
- 23 July 2014
- journal article
- research article
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 40 (7) , 1901-1906
Abstract
Our aim was to analyze the effect of reducing the dose of depot gonadotrophin-regulating hormone-agonist (GnRH-a) to 1.0 mg on pituitary desensitization and clinical outcome of in vitro fertilization and embryo transfer cycles. This retrospective self-control study was conducted on 143 patients who underwent repeated long-protocol treatment from 1 January 2011 to 31 May 2012 at our hospital. Of the 143 patients, 64 received reduced-dose depot (1.0 mg diphereline depot) GnRH-a for the first cycle and short-acting GnRH-a (0.05 mg diphereline) for the second cycle, while 79 patients received short-acting GnRH-a for the first cycle and reduced-dose depot GnRH-a for the second cycle. The serum follicle-stimulating hormone, luteinizing hormone and estradiol levels on the day of gonadotrophin initiation were significantly higher in the short-acting group compared with the long-acting group. Both number of days of gonadotrophin stimulation and gonadotrophin doses were significantly higher in the short-acting group. On the day of human chorionic gonadotrophin administration, the serum estradiol level was significantly higher while the progesterone level was significantly lower in the short-acting group. There were no significant differences with regard to the number of retrieved oocytes, fertilization rate, number of transferred embryos, clinical pregnancy rate, implantation rate, and early pregnancy loss rate between the two groups. However, the oocyte maturation rate was significantly higher in the long-acting group. Reduced-dose depot GnRH-a can be successfully used for pituitary desensitization in in vitro fertilization and embryo transfer. Deeper downregulation with reduced-dose depot GnRH-a indicates that the optimal dose of GnRH-a warrants future study.Keywords
Funding Information
- Medical Scientific Research Funds of Guangdong Province (B2012091)
This publication has 20 references indexed in Scilit:
- Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: an analysis of 2,566 cyclesFertility and Sterility, 2012
- Clinical outcome of one-third–dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulationJournal of Human Reproductive Sciences, 2012
- Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administrationFertility and Sterility, 2011
- Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cyclesArchives of Medical Science, 2010
- The ratio of late-follicular to mid-follicular phase LH concentrations efficiently predicts ART outcomes in women undergoing ART treatment with GnRH-agonist long protocol and stimulation with recombinant FSHJournal of Assisted Reproduction and Genetics, 2008
- Comparison of Clinical Efficacy between a Single Administration of Long-Acting Gonadotrophin-Releasing Hormone Agonist (GnRHa) and Daily Administrations of Short-Acting GnRHa in In Vitro Fertilization-Embryo Transfer CyclesJournal of Korean Medical Science, 2008
- Intracytoplasmic sperm injection (ICSI) in 2006: Evidence and EvolutionHuman Reproduction Update, 2007
- Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysisHuman Reproduction Update, 2007
- Maximizing Pregnancy Rates and Limiting Higher-Order Multiple Conceptions by Determining the Optimal Number of Embryos to Transfer Based on QualityFertility and Sterility, 1998
- The significance of elevated progesterone at the time of administration of human chorionic gonadotropin may be related to luteal supportJournal of Assisted Reproduction and Genetics, 1996